Covering the Bases in Cardioversion

Program Goals and Talking Points

Patient Case : Scenario 1

Patient Case: Scenario 2

Cardioversion and the Risk for Stroke

Asymptomatic Episodes

Endocardial Remodeling

Symptomatic vs Asymptomatic AF

REVEAL AF: AF Incidence by CHADS2 Subgroup

Selecting an Anticoagulant: Convenience Counts

Persistence of Anticoagulants Following AF

NOAC Dosing

Other factors to Consider

ENSURE-AF Study Design

ENSURE-AF: Event Rates

Advantages of Using NOACs During Cardioversion

ENSURE-AF: Event Rates By Age and Gender

Stroke Risk vs Bleeding Risk

Short Duration of AF May confer risk

Abbreviations

Abbreviations (cont)